Unicorn Nest Logo

HT Capital

htcapital.org
Total investments

19

Average round size

26M

Portfolio companies

15

Stages of investment
SeedPrivate EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsManufacturingMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Investments analytics

Analytics

Total investments
19
Lead investments
0
Investments by industry
  • Biotechnology (10)
  • Health Care (7)
  • Medical Device (3)
  • Biopharma (3)
  • Medical (2)
    • Show 22 more
Investments by region
  • United States (9)
  • China (2)
  • Japan (2)
  • Israel (2)
  • Taiwan (1)
Peak activity year
2018
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.
Sign Up

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
106M
Group Appearance index
0.89

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Upgrade

Latest deals

Company name Deal date Industry Deal stage Deal size Location
EquipmentShare 24 Jan 2017 Rental, Construction, Service Industry, Fleet Management Early Stage Venture 26M United States, Missouri, Columbia
Kula Bio 03 Jan 2022 Biotechnology, Food and Beverage, Agriculture, Farming Early Stage Venture 50M United States, Massachusetts
25 Oct 2018 Biotechnology, Artificial Intelligence, Pharmaceutical Early Stage Venture 46M United States, Cambridge
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.